全文获取类型
收费全文 | 919篇 |
免费 | 67篇 |
国内免费 | 28篇 |
专业分类
儿科学 | 61篇 |
妇产科学 | 12篇 |
基础医学 | 79篇 |
口腔科学 | 48篇 |
临床医学 | 113篇 |
内科学 | 166篇 |
皮肤病学 | 13篇 |
神经病学 | 16篇 |
特种医学 | 253篇 |
外科学 | 55篇 |
综合类 | 19篇 |
预防医学 | 31篇 |
眼科学 | 6篇 |
药学 | 45篇 |
肿瘤学 | 97篇 |
出版年
2023年 | 2篇 |
2021年 | 5篇 |
2019年 | 6篇 |
2018年 | 16篇 |
2017年 | 7篇 |
2016年 | 7篇 |
2015年 | 14篇 |
2014年 | 18篇 |
2013年 | 12篇 |
2012年 | 9篇 |
2011年 | 15篇 |
2010年 | 35篇 |
2009年 | 22篇 |
2008年 | 10篇 |
2007年 | 29篇 |
2006年 | 24篇 |
2005年 | 19篇 |
2004年 | 12篇 |
2003年 | 24篇 |
2002年 | 20篇 |
2001年 | 19篇 |
2000年 | 16篇 |
1999年 | 18篇 |
1998年 | 60篇 |
1997年 | 71篇 |
1996年 | 78篇 |
1995年 | 47篇 |
1994年 | 40篇 |
1993年 | 43篇 |
1992年 | 18篇 |
1991年 | 12篇 |
1990年 | 19篇 |
1989年 | 40篇 |
1988年 | 40篇 |
1987年 | 30篇 |
1986年 | 30篇 |
1985年 | 32篇 |
1984年 | 10篇 |
1983年 | 10篇 |
1982年 | 12篇 |
1981年 | 10篇 |
1980年 | 12篇 |
1979年 | 3篇 |
1978年 | 4篇 |
1977年 | 13篇 |
1976年 | 10篇 |
1975年 | 6篇 |
1969年 | 1篇 |
1966年 | 1篇 |
1950年 | 1篇 |
排序方式: 共有1014条查询结果,搜索用时 15 毫秒
71.
72.
73.
Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma 总被引:7,自引:0,他引:7
BACKGROUND: Accurate assessment of HER-2 status is necessary prior to anti-HER-2 antibody (trastuzumab) therapy for metastatic breast carcinoma. However, controversy exists regarding whether to assess HER-2 status in the primary tumor or in metastatic lesions. It is also unclear whether HER-2 status can change during disease progression or after chemotherapy. METHODS: Breast carcinoma samples from 60 women with known HER-2 status in both primary tumors and paired metastases (locoregional disease, n = 43 patients; distant disease, n = 17 patients) were reviewed retrospectively. Thirty-two patients underwent chemotherapy before their metastatic lesions were sampled, including 18 patients who received neoadjuvant chemotherapy and 14 patients who received adjuvant chemotherapy. The HER-2 gene was examined by fluorescence in situ hybridization either in paraffin-embedded tissue samples (48 primary tumors and 9 metastatic tumors) or in fine-needle aspirates (12 primary tumors and 51 metastatic tumors). HER-2 gene amplification was defined as a HER-2:chromosome 17 signal ratio >/= 2.0. RESULTS: The HER-2 status of primary and metastatic tumors agreed in 58 of 60 patients (97%), including 18 (30%) amplified tumors and 40 (67%) nonamplified tumors. A discrepancy in HER-2 status was observed in specimens from two patients in which HER-2 amplification was detected in the primary tumor but not the metastatic tumors. In one patient, three foci of tumor nodules were found in the same breast; the HER-2 status was assessed in only one of them, which showed amplification; however, HER-2 amplification was not detected in the axillary lymph node metastasis. In another patient, the HER-2 gene was amplified in the primary tumor but not in the liver metastasis. No metastases showed HER-2 amplification without amplification in the primary tumor. Locoregional and distant metastases demonstrated similar concordance rates with their corresponding primary tumors (98% and 94%, respectively). Complete concordance of HER-2 status was found between primary tumors prior to chemotherapy and metastases that were sampled after chemotherapy. CONCLUSIONS: The HER-2 status in breast carcinoma generally was stable during metastasis, whether to locoregional or distant sites. Chemotherapy did not modify the HER-2 status in metastatic lesions. Therefore, HER-2 amplification can be evaluated reliably in material from either primary or metastatic tumors in most patients. Further study with larger series is warranted to elucidate the significance of discordant results. 相似文献
74.
Pusztai L Wagner P Ibrahim N Rivera E Theriault R Booser D Symmans FW Wong F Blumenschein G Fleming DR Rouzier R Boniface G Hortobagyi GN 《Cancer》2005,104(4):682-691
BACKGROUND: The primary objective of this study was to determine whether addition of the selective P-glycoprotein (P-gp) inhibitor tariquidar (XR9576) to chemotherapy could induce an objective tumor response in patients who previously were resistant to the same agents. The secondary objectives were to evaluate P-gp expression by immunohistochemistry (IHC), to determine functional activity of the P-gp transporter before and after administration of tariquidar with serial technetium-99m ((99m)Tc)-sestamibi scans, and to correlate those parameters with clinical response. METHODS: Seventeen women with Stage III-IV breast carcinoma were included in the study who progressed (n = 13 women) or had stable disease (n = 4 women) on doxorubicin-containing or taxane-containing chemotherapy regimens. During the study, the same chemotherapy was continued without dose modifications, but tariquidar (150 mg intravenously) was added to the treatment regimen. RESULTS: Thirty-six percent of patients had P-gp-positive tumors by IHC, and 5 patients (29%) experienced increases > or = 10% in sestamibi uptake (median increase, 40%; range, 10-63%) after the administration of tariquidar. There was one partial response in a patient who had the greatest increase in sestamibi uptake and who also showed inducible P-gp expression. There was one patient who experienced severe doxorubicin/docetaxel-related toxicity after tariquidar was added to her chemotherapy regimen. CONCLUSIONS: Tariquidar showed limited clinical activity to restore sensitivity to anthracycline or taxane chemotherapy. Functional imaging of the tumor with (99m)Tc-sestamibi scans before and after administration of multidrug-resistance inhibitor may be useful to identify the small subset of patients who could benefit from multidrug-resistance modulation in future trials. 相似文献
75.
Thoracic wall involvement by Hodgkin disease and non-Hodgkin lymphoma: CT evaluation 总被引:6,自引:0,他引:6
Thoracic computed tomographic (CT) scans of 250 patients with newly diagnosed or recurrent lymphoma revealed thoracic wall involvement in 24 patients (11 with Hodgkin disease, 13 with non-Hodgkin lymphoma). Thoracic wall involvement occurred without contiguous mediastinal or parenchymal involvement in 17 patients. Of these, 13 patients had masses beneath the pectoralis muscles or within the breast, and four had masses arising from the ribs. Five additional patients had mediastinal masses with thymic involvement and parasternal extension through the thoracic wall. Pulmonary parenchymal lymphoma with thoracic wall invasion was noted in the remaining two patients. In five of nine patients receiving radiation therapy, treatment plans were modified by CT demonstration of thoracic wall lymphoma. 相似文献
76.
T Umsawasdi M Valdivieso H T Barkley D J Booser D F Chiuten W K Murphy H M Dhingra C L Dixon P Farha G Spitzer 《International journal of radiation oncology, biology, physics》1985,11(3):511-519
Esophageal complications from combined chemoradiotherapy (CCRT) were analyzed in 55 patients with limited non-small cell lung cancer. CCRT consisted of chemotherapy (cyclophosphamide, doxorubicin (Adriamycin), and cisplatin: CAP) and chest irradiation (5000 rad in 25 fractions/5 weeks). Forty-five patients received two courses of CAP, followed by five weekly courses of low dose CAP and irradiation followed by maintenance courses of CAP (Group 1). Ten patients received concomitant CCRT from the onset of treatment (Group 2). Esophagitis occurred in 80% of all patients. Severe esophagitis occurred in 27% of patients of Group 1 and 40% of patients of Group 2. Esophageal stricture or fistula developed in 1 of 45 (2%) patients in Group 1, and 3 of 10 (30%) patients in Group 2 (p less than 0.025). Weekly low-dose chemotherapy administered concomitantly with chest irradiation (R) at the onset of treatment significantly increases esophageal complications. A review of the literature suggests that CCRT may be used safely with split courses of R. The duration between onset of chemotherapy either before or after R should be greater than one week. 相似文献
77.
McRedmond JP Mulvihill NT Kane M Burke B Aloul B Forde T Walsh M Fitzgerald DJ 《Irish journal of medical science》2004,173(4):204-210
Background Streptokinase resistance may cause suboptimal thrombolytic therapy.
Aim To develop a rapid latex-bead assay to detect streptokinase antibodies.
Methods Sera were obtained from 16 patients presenting with acute myocardial infarction (MI) before treatment with streptokinase
and 1 and 6 months post treatment, and from 100 controls. Sera were assayed for anti-streptokinase antibodies using a functional
streptokinase-neutralising assay.
Results Streptokinase-neutralising activity was low in controls (54±5U/ml) and patients prior to treatment (101±18), increasing to
2,110±823 and 1,017±169 at 1 and 6 months (mean±SEM). The latex assay had a sensitivity of 94% and a specificity of 93% for
detecting individuals with >350U/ml of streptokinase resistance, which is sufficient to neutralise the drug clinically.
Conclusions Estimation of streptokinase resistance using an enzyme immunoassay and a latex bead assay correlated well with serum neutralising
activity. This assay can rapidly identify patients who have a high level of streptokinase-neutralising activity. 相似文献
78.
79.
Oscillatory motion of the normal cervical spinal cord 总被引:2,自引:0,他引:2
80.
Coralline hydroxyapatite bone graft substitutes: preliminary report of radiographic evaluation 总被引:1,自引:0,他引:1
A new bone graft substitute made by conversion of the calcium carbonate exoskeleton of reef-building sea coral into hydroxyapatite has recently become clinically available. The normal radiographic appearance of two forms of this material is described. In the immediate postoperative period, the exoskeletal architecture of these implants is readily appreciated. With graft incorporation over the ensuing months, their intrinsic structure is gradually lost in association with poor marginal definition. Evolving radiographic findings reflect the biocompatible nature of these implants, which provides the potential for ingrowth of native bone with preservation of the coralline scaffold, resulting in enhanced biomechanical properties. 相似文献